Investigators established a stable cisplatin (CDDP)-resistant derivative of the HT1376 bladder cancer cell line by stepwise exposure to escalating CDDP concentrations. The protocol escalated from very low starting levels to a final culture concentration of 1.5 µg/mL. The resulting HT1376-CR cells displayed a more rapid proliferation rate in vitro and an IC50 for CDDP more than threefold higher than parental HT1376/P cells, indicating successful acquisition of resistance. The authors reported proliferation and viability measurements were normalized across experiments and derived from three independent replicates.
The study team compared responses to enfortumab vedotin (EV) between HT1376/P and HT1376-CR using viability assays and a mouse xenograft model. In vitro, HT1376-CR cells showed lower viability than parental cells across the EV concentration range tested, signifying enhanced EV sensitivity. In vivo, female BALB/c nude mice bearing subcutaneous HT1376/P or HT1376-CR tumors received weekly intraperitoneal EV at 1 mg/kg for three weeks or vehicle. EV reduced tumor growth in both models. Quantitative analysis used relative tumor volume (RTV) normalized to baseline; a two-way ANOVA of log-transformed RTV at day 22 produced a significant interaction between tumor model and treatment (p = 0.039), which the authors interpreted as a differential antitumor effect of EV in the resistant versus parental tumors.
The study measured nectin-4 protein by immunoblotting and cell-surface expression by flow cytometry. Immunoblots and mean fluorescence intensity (MFI) analysis showed that HT1376-CR had reduced total and cell-surface nectin-4 compared with HT1376/P. Flow cytometric EV-binding assays likewise demonstrated decreased EV binding to HT1376-CR cells. The authors reported this paradox—reduced target expression yet increased functional sensitivity—and presented the raw immunoblot images and supporting data in supplemental files.
To probe payload susceptibility, investigators tested the free payload, MMAE, in viability and cell-cycle assays. HT1376-CR cells were more sensitive to MMAE than parental cells in cell viability assays conducted three days after exposure. Flow cytometry after 24-hour MMAE exposure revealed a greater accumulation of HT1376-CR cells in the G2/M phase compared with treated parental cells. The study team interpreted these findings to mean that enhanced payload susceptibility and augmented mitotic arrest contribute to the increased efficacy of the ADC in the resistant subline.
Expression profiling by quantitative PCR and immunoblotting identified marked upregulation of ABCB1 in HT1376-CR relative to HT1376/P. The authors performed RNA interference using two ABCB1-targeting siRNAs and validated knockdown by immunoblot. ABCB1 suppression increased sensitivity of HT1376-CR cells to CDDP, MMAE, and enfortumab vedotin in cell viability assays. These experiments implicated ABCB1 as a modulatory factor for multi-drug responses in the resistant model and suggested that transporter-mediated efflux can influence payload and ADC activity in this context.
The report provides detailed preclinical methodology, including cell-culture conditions, viability assays (CCK-8), cycle analysis, flow cytometry protocols, western blotting, and the xenograft dosing regimen used. Investigators noted that all primary data and original immunoblots appear in supporting files. The study did not include clinical patient data, long-term toxicity assessments, or exploration of combination regimens beyond ABCB1 silencing. The source did not report detailed pharmacokinetic or biodistribution analyses for EV in the xenograft experiments. Additional unanswered questions documented by the authors include the mechanistic basis for reduced nectin-4 concurrent with increased payload sensitivity and whether the ABCB1 effect observed in vitro translates to clinical settings. The manuscript ends with these experimental limitations and open mechanistic questions rather than broader clinical recommendations.